

-19-

5 We Claim:

1. A method for treating a mammal exhibiting type 2 diabetes or metabolic syndrome comprising: administering to said mammal a therapeutically effective amount of FGF-21 or an FGF-21 compound in combination with a thiazolidinedione sufficient to
10 achieve in said mammal at least one of the following modifications: reduction in triglycerides, decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, or reduction of hyperglycemia.
2. The method of Claim 1 wherein said mammal is a human subject which
15 exhibits type 2 diabetes.
3. The method of Claim 1 wherein said mammal is a human subject which exhibits metabolic syndrome.
- 20 4. The method of Claim 1 wherein said modification is a reduction of hyperglycemia.
5. The method of Claim 1 wherein said modification is a reduction in triglycerides.
25
6. The method of Claim 1 wherein said thiazolidinedione is selected from the group consisting of rosiglitazone or pioglitazone.
7. The method of Claim 6 wherein said thiazolidinedione is rosiglitazone.
30
8. The method of Claim 6 wherein said thiazolidinedione is pioglitazone.